These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28122430)

  • 1. Exosome-Based Delivery of miR-124 in a Huntington's Disease Model.
    Lee ST; Im W; Ban JJ; Lee M; Jung KH; Lee SK; Chu K; Kim M
    J Mov Disord; 2017 Jan; 10(1):45-52. PubMed ID: 28122430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supplemental Treatment for Huntington's Disease with miR-132 that Is Deficient in Huntington's Disease Brain.
    Fukuoka M; Takahashi M; Fujita H; Chiyo T; Popiel HA; Watanabe S; Furuya H; Murata M; Wada K; Okada T; Nagai Y; Hohjoh H
    Mol Ther Nucleic Acids; 2018 Jun; 11():79-90. PubMed ID: 29858092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement.
    Hoss AG; Labadorf A; Latourelle JC; Kartha VK; Hadzi TC; Gusella JF; MacDonald ME; Chen JF; Akbarian S; Weng Z; Vonsattel JP; Myers RH
    BMC Med Genomics; 2015 Mar; 8():10. PubMed ID: 25889241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes from adipose-derived stem cells ameliorate phenotype of Huntington's disease in vitro model.
    Lee M; Liu T; Im W; Kim M
    Eur J Neurosci; 2016 Aug; 44(4):2114-9. PubMed ID: 27177616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of miR-9* in the peripheral leukocytes of Huntington's disease patients.
    Chang KH; Wu YR; Chen CM
    Orphanet J Rare Dis; 2017 Dec; 12(1):185. PubMed ID: 29258536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential microRNA expression in the SH-SY5Y human cell model as potential biomarkers for Huntington's disease.
    Belkozhayev A; Niyazova R; Kamal MA; Ivashchenko A; Sharipov K; Wilson CM
    Front Cell Neurosci; 2024; 18():1399742. PubMed ID: 39049823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic exosome-derived miR-130a-3p attenuates glucose intolerance via suppressing PHLPP2 gene in adipocyte.
    Wu J; Dong T; Chen T; Sun J; Luo J; He J; Wei L; Zeng B; Zhang H; Li W; Liu J; Chen X; Su M; Ni Y; Jiang Q; Zhang Y; Xi Q
    Metabolism; 2020 Feb; 103():154006. PubMed ID: 31715176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating microRNAs in Huntington's disease: Emerging mediators in metabolic impairment.
    Díez-Planelles C; Sánchez-Lozano P; Crespo MC; Gil-Zamorano J; Ribacoba R; González N; Suárez E; Martínez-Descals A; Martínez-Camblor P; Álvarez V; Martín-Hernández R; Huerta-Ruíz I; González-García I; Cosgaya JM; Visioli F; Dávalos A; Iglesias-Gutiérrez E; Tomás-Zapico C
    Pharmacol Res; 2016 Jun; 108():102-110. PubMed ID: 27155059
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Wang B; Zhang A; Wang H; Klein JD; Tan L; Wang ZM; Du J; Naqvi N; Liu BC; Wang XH
    Theranostics; 2019; 9(7):1864-1877. PubMed ID: 31037144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of mitochondrial morphology and cell cycle by microRNA-214 targeting Mitofusin2.
    Bucha S; Mukhopadhyay D; Bhattacharyya NP
    Biochem Biophys Res Commun; 2015 Oct; 465(4):797-802. PubMed ID: 26307536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomes and Homeostatic Synaptic Plasticity Are Linked to Each other and to Huntington's, Parkinson's, and Other Neurodegenerative Diseases by Database-Enabled Analyses of Comprehensively Curated Datasets.
    Wang JKT; Langfelder P; Horvath S; Palazzolo MJ
    Front Neurosci; 2017; 11():149. PubMed ID: 28611571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.
    Ban JJ; Chung JY; Lee M; Im W; Kim M
    Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum.
    Chen CM; Wu YR; Chang KH
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
    Crocker SF; Costain WJ; Robertson HA
    Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Expression of Plasma Exo-miRNA in Neurodegenerative Diseases by Next-Generation Sequencing.
    Nie C; Sun Y; Zhen H; Guo M; Ye J; Liu Z; Yang Y; Zhang X
    Front Neurosci; 2020; 14():438. PubMed ID: 32457573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of Novel Drug Delivery System Targeting Exosomal microRNA].
    Yamayoshi A
    Yakugaku Zasshi; 2020; 140(5):625-631. PubMed ID: 32378662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.
    Spires TL; Grote HE; Garry S; Cordery PM; Van Dellen A; Blakemore C; Hannan AJ
    Eur J Neurosci; 2004 May; 19(10):2799-807. PubMed ID: 15147313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
    Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
    Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.